Higher Levels of PrEP Use Associated with Reduction in HIV Diagnoses
Findings from a CDC study showing that increased use of pre-exposure prophylaxis (PrEP) is strongly linked to a decline in new HIV diagnoses in the U.S. Between 2012 and 2022, as PrEP use rose significantly—especially among men who have sex with men—HIV diagnoses dropped by 12%. The study emphasizes that scaling up equitable access to PrEP, particularly among disproportionately affected groups like Black and Latino communities, is essential to further reducing HIV transmission and achieving national HIV prevention goals. Full Access: AJMC
Surge in Pediatric Mycoplasma Pneumoniae Hospitalizations Reported in 2024
In 2024, Mycoplasma pneumoniae was implicated in about one-third of pediatric community-acquired pneumonia (CAP) hospitalizations in the U.S., peaking at 53.8% in July—a significant jump from prior years. Children aged 6–12 were most affected (42.6%), but marked increases were also seen in younger groups, including infants under 12 months (8-fold rise). Despite more hospitalizations, cases in 2024 were less severe, with shorter average stays (2 vs. 3 days), fewer ICU admissions (19.5% vs. 26%), and lower in-hospital mortality (0.1% vs. 0.5%) . Nearly all patients (96%) received appropriate macrolide treatment. Full Access: Contemporary Pediatrics
Impact of Pediatric Antimicrobial Stewardship Program in Hematogenous Bone and Joint Infections
Researchers evaluate how implementing a pediatric antimicrobial stewardship program (ASP) influenced the management of bone and joint infections in children. The study found that the ASP led to more appropriate antibiotic use, including reduced use of broad-spectrum agents and shorter durations of intravenous therapy. Importantly, these changes did not compromise clinical outcomes, suggesting that stewardship programs can optimize antibiotic therapy while maintaining patient safety and effectiveness in treating serious infections. Full Access: European Journal of Pediatrics
Study Shows Promising Results for Inhaled Insulin as Treatment for Type 1 Diabetes
Findings from INHALE-3, a pivotal trial examining the use of inhaled insulin in adults with type 1 diabetes (T1D), were announced, highlighting the potential of an alternative insulin solution to enhance diabetes management. The results were presented as a symposium at the 84th Scientific Sessions of the American Diabetes Association® (ADA). Full Access: ADA